Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses the importance of individualized approaches to determine the best duration of immunotherapy treatment. Specifically, he focuses on the need to optimize patient outcomes and reducing unnecessary costs. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.